Fluoxetine-Associated Tinnitus Incidence
The FDA drug label data does not specifically report tinnitus as a distinct adverse event in fluoxetine clinical trials, making it impossible to provide an exact percentage. However, based on the available evidence, tinnitus appears to be an uncommon side effect of fluoxetine treatment.
What the Evidence Shows
FDA Label Data
The official fluoxetine (Prozac) prescribing information 11 does not list tinnitus among the adverse events that occurred in ≥2% of patients or among the most common treatment-emergent adverse events (those occurring in ≥5% of patients and at least twice the placebo rate). This absence from the standardized reporting tables suggests tinnitus occurs in less than 2% of patients taking fluoxetine.
Real-World Surveillance Data
A comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database from 2012-2023 examined 29,460 patients with drug-related tinnitus 2. While duloxetine showed the strongest association with tinnitus (ROR 11.99), fluoxetine was mentioned but did not rank among the top 25 tinnitus-associated drugs. This suggests fluoxetine has a relatively lower risk profile for tinnitus compared to other antidepressants.
Clinical Context
Importantly, fluoxetine has been studied as a treatment for tinnitus rather than primarily as a cause 345. In a 2025 network meta-analysis, fluoxetine ranked first for reducing tinnitus loudness (SMD: -3.28) compared to placebo 3. This therapeutic application suggests that when tinnitus does occur with fluoxetine, it may be coincidental or related to underlying conditions rather than drug-induced.
Important Caveats
- Baseline tinnitus prevalence: General population tinnitus affects 10-15% of adults 6, making it difficult to distinguish drug-induced from pre-existing or coincidental tinnitus
- Depression-tinnitus overlap: Depression commonly co-occurs with tinnitus 5, so patients prescribed fluoxetine may already have higher baseline tinnitus rates
- Reporting limitations: The FDA label notes that "events reported during therapy were not necessarily caused by it" 1, and tinnitus may have been underreported or classified under other categories
Clinical Bottom Line
Fluoxetine-associated tinnitus occurs in less than 2% of patients based on FDA clinical trial data, and likely represents a rare adverse event. The drug's documented efficacy in treating tinnitus 34 further suggests it is not a significant causative agent. When prescribing fluoxetine, clinicians should be aware that tinnitus is possible but uncommon, and should not be a primary concern when weighing the medication's benefits against risks.